p53 gene mutations – PharmaLive

FDA Pauses Enrollment for Aprea’s Lymphoid Malignancy Trial

Business, Clinical Hold, Clinical Trials, Lymphoid Malignancy, Myelodysplastic Syndromes, Orphan Drug Designation, p53 gene mutations, Patient Enrollment, R&D, Shares

The U.S. Food and Drug Administration placed a clinical hold on Boston-based Aprea Therapeutics’ lymphoid malignancy trial after the regulatory agency expressed concerns regarding the safety and efficacy data from a previous myelodysplastic syndromes (MDS) study.

August 13, 2021/by BioSpace

Tapeworm drug could be an effective treatment for certain cancers

Antiparasitics, Cancer, Cancer Cells, Colon Cancer, FDA, Medical Journals, Methicillin-Resistant Staphylococcus Aureus (MRSA), Nature Communications, p53 gene mutations, R&D, Tapeworms, World Health Organization

Researchers in Singapore believe that a drug used to treat tapeworms can be effective at treating a type of cancer.

February 19, 2019/by BioSpace